Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bosentan.

Kelly Chin1, Richard Channick

  • 1Division of Pulmonary and Critical Care Medicine, University of California, San Diego, 9300 Campus Point Drive, La Jolla, CA 92037-7381, USA. kmchin@ucsd.edu

Expert Review of Cardiovascular Therapy
|May 21, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biological Sex Differences in the US-CTEPH-R.

Annals of the American Thoracic Society·2026
Same author

Methamphetamine-associated PAH on the rise in the US: geographic trends & disparities in patient demographics and treatment strategies.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026
Same author

A normal BNP does not reliably exclude pulmonary hypertension in interstitial lung disease.

The European respiratory journal·2025
Same author

Preferences for pulmonary arterial hypertension (PAH) medications: plain language summary on insights from interviews with patients and doctors in the A DUE phase 3 clinical study.

Future cardiology·2025
Same author

Healthcare Resource Utilization and Outcomes in Intermediate-Risk Pulmonary Embolism in the United States.

The American journal of cardiology·2025
Same author

In Situ Pulmonary Artery Thrombosis and Low Flow Stasis Artifact in Parenchymal Lung Disease: An Under-Recognized Phenomenon.

Pulmonary circulation·2025

Bosentan, an oral endothelin receptor antagonist, improved symptoms and exercise capacity in pulmonary arterial hypertension patients. Long-term data shows sustained benefits, offering a convenient treatment option.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Pulmonary Medicine

Background:

  • Pulmonary arterial hypertension (PAH) is a severe condition requiring effective treatment.
  • Oral dual endothelin receptor antagonists represent a therapeutic advance.
  • Bosentan is approved for functional class III to IV PAH.

Purpose of the Study:

  • To evaluate the efficacy and safety of bosentan in PAH patients.
  • To assess long-term outcomes and patient response to bosentan therapy.
  • To explore potential new applications for bosentan.

Main Methods:

  • Two placebo-controlled trials were conducted.
  • Patients were assessed for functional class and 6-minute walk distance.
  • Hemodynamic parameters were monitored.

Related Experiment Videos

Main Results:

  • Bosentan significantly improved functional class and 6-minute walk distance over 12–16 weeks.
  • The majority of patients maintained their response to bosentan over 3 years.
  • Ongoing investigations explore bosentan as an add-on therapy for severe PAH and its antifibrotic properties.

Conclusions:

  • Bosentan is an effective oral treatment for PAH, offering sustained benefits.
  • Its twice-daily oral dosing provides a convenient alternative to intravenous medications.
  • Further research is exploring bosentan's role in severe PAH and pulmonary fibrosis.